Submission of revised Investors Presentation

Date: 4th August 2026 National Stock Exchange of India Limited BSE Limited Phiroze Jeejeebhoy Towers Exchange Plaza, C-1, Block G Bandra Kurla Dalal Street, Mumbai – 400001 Complex, Bandra (E), Mumbai – 400051 Scrip Code: 544619 Scrip Symbol- SUDEEPPHRM Sub: Q1FY27 - Result Presentation Ref: Regulation 30 of the SEBI (LODR) Regulations, 2015 as amended from time to time Dear Sir/Ma’am, In continuation to our letter dated 27th July 2026 regarding intimation of Earnings Call of the Company scheduled on Wednesday, 5th August 2026 at 11:00 a.m. to discuss the operational & financial performance of the Company for the quarter ended on 30th June 2026, kindly find enclosed herewith Revised Q1FY27 Result Presentation of the Company. Copy of Revised Q1FY27 Result Presentation is annexed herewith and is also hosted on our website https://www.sudeeppharma.com/. Kindly take the same on record. Thanking You. For Sudeep Pharma Limited Dimple Mehta Company Secretary & Compliance Officer M. No.: F13184 ENCL: A/a CIN: L24231GJ1989PLC013141 Registered Office: 129/1/A, G.I.D.C. Estate Nandesari, Baroda-391340, Gujarat, India. Phone No.: +91 265 2840656, 7624095107 Corporate Office: 601, 602, 6th Floor, Sears Towers-2, Gotri-Sevasi Road, Sevasi, Vadodara-390021, Gujarat, India Website: www.sudeepgroup.com, Email ID: mail@sudeepgroup.com Sudeep Pharma Limited Investor Presentation August 2026 Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Sudeep Pharma Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. This presentation contains certain forward looking statements concerning the Company’s future business prospects and business profitability, which are subject to a number of risks and uncertainties and the actual results could materially differ from those in such forward looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, competition (both domestic and international), economic growth in India and abroad, ability to attract and retain highly skilled professionals, time and cost over runs on contracts, our ability to manage our international operations, government policies and actions regulations, interest and other fiscal costs generally prevailing in the economy. The Company does not undertake to make any announcement in case any of these forward looking statements become materially incorrect in future or update any forward looking statements made from time to time by or on behalf of the Company. Q1 FY27 Performance Highlights MD’s Message "We are pleased to report a strong start to FY27, with revenue growing 27% year-on-year, driven by broad-based performance across our Pharma, Food & Nutrition, and Specialty Ingredients businesses. The quarter was marked by a challenging global environment characterised by geopolitical uncertainties, supply chain disruptions, intermittent gas supply constraints, and elevated logistics costs. Despite these headwinds, we delivered a resilient performance supported by continued operational excellence initiatives, improved manufacturing efficiencies, and disciplined cost management. Our strategic growth initiatives continue to make encouraging progress. The Greenfield expansion remains on track, with regulatory approvals progressing as planned and customer qualification activities advancing steadily. Once operational, the facility will significantly enhance our manufacturing capabilities, broaden our product portfolio, and support the growing demand for our high-value, technology-driven solutions. We are also making great progress on our Sudeep Advanced Materials (SAM) project, in line with our planned timelines to commission by March 2027. Encouraged by strong customer engagement and increasing visibility on future off-take opportunities, we have initiated planning for Phase 2, reinforcing our confidence in the long-term growth potential of the advanced battery materials business. At NSS, while the European market continues to remain subdued, integration efforts are progressing well. We continue to execute our integration roadmap across commercial, supply chain, procurement, and operational functions, which we believe will drive greater efficiencies, strengthen customer relationships, and enhance profitability over the medium term. We also remain focused on improving capital efficiency through disciplined working capital management and continue to make steady progress towards our internal targets. Supported by a diversified business portfolio, deep and long-standing customer relationships, an expanding global footprint, and multiple growth initiatives progressing as planned, we remain well positioned to navigate an evolving global environment. Mr. Sujit Bhayani We are confident that our differentiated capabilities, disciplined execution, and continued investments in innovation and capacity will enable us to deliver sustainable long-term growth and create enduring value for all our Managing Director stakeholders." Q1 FY27 Performance Highlights Revenue from Operations EBITDA & Margin % PAT & Margin % Rs. Cr. Rs. Cr. Rs. Cr. 35.1% 34.7% 34.6% 25.0% 25.6% 27.1% 642.3 221.9 174.3 +27% +25% +30% 124.9 158.3 43.9 54.9 40.6 31.3 Q1FY26 Q1FY27* FY26* Q1FY26 Q1FY27* FY26* Q1FY26 Q1FY27* FY26* Revenue Breakup % Geographical Breakup % 100% 100% 100% 100% 100% 100% 34% 31% 44% 41% 31% 40% 66% 69% 69% 56% 59% 60% Q1FY26 Q1FY27* FY26* Q1FY26 Q1FY27* FY26* Speciality Ingredients Pharma & Food Nutrition Domestic Exports *NSS has started contributing to the revenue from 22nd May 2025 Q1 FY27 Key Highlights • Revenue from operations for Q1FY27 stood at Rs. 158.3 Cr, registering a strong 27% year-on-year growth despite multiple challenges like geopolitical uncertainties, intermittent gas supply constraints, elevated logistics costs, and continued container shortages across key trade routes • The Greenfield expansion project remains on schedule and is set to become the next growth platform for the Company's core Pharma, Food & Nutrition business. Regulatory approvals continue to progress as planned, while customer qualification activities have gained strong momentum with multiple customer audits scheduled. • The operating environment in Europe remained challenging during the quarter, with elevated energy costs impacting industrial activity and resulting in subdued demand across certain NSS customer segments. • The Specialty Ingredients business delivered another strong quarter, supported by robust growth in the Premix and Encapsulation portfolios, while the integration of NSS continues to progress as planned, strengthening the foundation for future growth and profitability. • Sudeep Advanced Materials (SAM) continues to make strong progress, with Phase 1 on track for commissioning by March 2027. Customer engagement continues to strengthen with an expanding qualification pipeline, two additional strateg [Showing first 8,000 characters — download PDF for full document]